Taiko Pharmaceutical Co.,Ltd. provided earnings guidance for the quarter end December 2021. For the quarter, the company expects Net sales to be JPY 12,500 million. Operating loss to be JPY 2,000 million. Basic loss per share to be JPY 64.62. Loss attributable to owners of parent to be JPY 2,800 million.